Stock Scorecard
Stock Summary for Esperion Therapeutics Inc (ESPR) - $2.40 as of 11/20/2024 4:02:07 PM EST
Total Score
7 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ESPR
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ESPR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ESPR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ESPR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ESPR (29 out of 90)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
Latest News for for ESPR
Financial Details for ESPR
Company Overview |
|
|---|---|
| Ticker | ESPR |
| Company Name | Esperion Therapeutics Inc |
| Country | USA |
| Description | Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 2.40 |
| Price 4 Years Ago | 26.00 |
| Last Day Price Updated | 11/20/2024 4:02:07 PM EST |
| Last Day Volume | 4,276,507 |
| Average Daily Volume | 4,266,558 |
| 52-Week High | 3.40 |
| 52-Week Low | 1.16 |
| Last Price to 52 Week Low | 106.90% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.60 |
| Sector PE | 40.32 |
| 5-Year Average PE | -4.04 |
| Free Cash Flow Ratio | 3.29 |
| Industry Free Cash Flow Ratio | 12.03 |
| Sector Free Cash Flow Ratio | 27.97 |
| Current Ratio Most Recent Quarter | 1.85 |
| Total Cash Per Share | 0.73 |
| Book Value Per Share Most Recent Quarter | -1.89 |
| Price to Book Ratio | 98.42 |
| Industry Price to Book Ratio | 5.31 |
| Sector Price to Book Ratio | 20.88 |
| Price to Sales Ratio Twelve Trailing Months | 1.61 |
| Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
| Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 197,035,000 |
| Market Capitalization | 472,884,000 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 10.45% |
| Reported EPS 12 Trailing Months | -0.67 |
| Reported EPS Past Year | -0.14 |
| Reported EPS Prior Year | -2.12 |
| Net Income Twelve Trailing Months | -86,771,000 |
| Net Income Past Year | -209,248,000 |
| Net Income Prior Year | -233,659,000 |
| Quarterly Revenue Growth YOY | 52.00% |
| 5-Year Revenue Growth | -20.84% |
| Operating Margin Twelve Trailing Months | -0.31 |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 144,717,000 |
| Total Cash Past Year | 82,248,000 |
| Total Cash Prior Year | 166,861,000 |
| Net Cash Position Most Recent Quarter | -118,205,000 |
| Net Cash Position Past Year | -179,348,000 |
| Long Term Debt Past Year | 261,596,000 |
| Long Term Debt Prior Year | 259,899,000 |
| Total Debt Most Recent Quarter | 262,922,000 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -454,994,000 |
| Total Stockholder Equity Prior Year | -323,778,000 |
| Total Stockholder Equity Most Recent Quarter | -370,209,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -26,075,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.13 |
| Free Cash Flow Past Year | 0 |
| Free Cash Flow Prior Year | 0 |
Options |
|
| Put/Call Ratio | 0.07 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.07 |
| MACD Signal | 0.07 |
| 20-Day Bollinger Lower Band | 1.56 |
| 20-Day Bollinger Middle Band | 2.04 |
| 20-Day Bollinger Upper Band | 2.52 |
| Beta | 0.95 |
| RSI | 50.66 |
| 50-Day SMA | 2.25 |
| 150-Day SMA | 3.57 |
| 200-Day SMA | 7.27 |
System |
|
| Modified | 11/21/2024 12:15:57 AM EST |